MicroRNA-30e Expression In Patients With Schizophrenia And Its Correlation With Clinical Efficacy

Purpose Schizophrenia is a complex,slowly developing brain disease that places a heavy burden on society and individuals.Schizophrenia is judged based on diagnostic criteria and the experience of clinicians,and lacks strong pathological and biochemical indicators.Therefore,effective biomarkers will help the early detection,diagnosis and treatment of patients with schizophrenia,which is very important for prognosis.micro RNA is a small,endogenous,non-coding single-stranded RNA with a length of22-25 nucleotides.It develops and matures in nerves,including process growth,differentiation,proliferation,dendritic development and Dendritic spine formation plays a role.Studies have shown that micro RNAs may play a key role in the progression of schizophrenia,but the diagnosis,treatment and specific mechanisms of micro RNA-30 e in schizophrenia are unclear.Therefore,this study aims to investigate the expression of micro RNA-30 e in patients with schizophrenia,further explore the relationship between its expression level and the symptomology of patients with schizophrenia,and evaluate its role in the diagnosis and treatment process.Methods Thirty patients with schizophrenia and 30 healthy controls were collected from the Seventh People's Hospital of Dalian.Real-time quantitative PCR was used to detect the levels of micro RNA-30 e in plasma of patients with schizophrenia,healthy controls and patients with schizophrenia before and after 6 weeks of treatment.Negative Symptom Scale(PANSS),Personal and Social Function Scale(PSP),Gross Assessment Scale(GAS),and Overall Clinical Efficacy Rating Scale(CGI)were used to determine the outcome and clinical efficacy of clinical symptoms.The result1.Compared with the control group,the micro RNA-30 e expression in the plasma of schizophrenia patients is relatively low(P <0.001).After 6 weeks of treatment with second-generation antipsychotic drugs(risperidone),micro RNA-30 e is expressed in the plasma of schizophrenia patients.The expression level was significantly increased(P<0.001),and there was no significant difference with the healthy control group(P>0.05).2.The expression level of plasma micro RNA-30 e in patients with schizophrenia has a negative correlation with the positive symptom P in the changes in the PANSS score before and after treatment(r =-0.735,p <0.001);it is negatively related to the risk of attack S of supplementary items.Correlation(r =-0.643,p <0.001);there was a positive correlation with changes in the General Assessment Scale(GAS)score(r = 0.717,p<0.001).3.The expression level of plasma micro RNA-30 e in patients with schizophrenia has no significant correlation with the negative symptoms N and the general psychiatric symptoms G and PSP scores in the changes of the PANSS scale scores,and there is no significant difference(p> 0.05)).Conclusion1.micro RNA-30 e may be involved in the progression of schizophrenia.2.The expression level of plasma micro RNA-30 e in patients with schizophrenia is related to the change of the overall condition,the outcome of positive symptoms,emotional stability,and behavioral impulsivity.The expression level of plasma micro RNA-30 e in patients with schizophrenia has no obvious relationship with social function(beneficial to social activities,interpersonal and social relations,self-care,interference and aggressive behavior)and disease severity,suggesting that micro RNA-30 e may become an observation Indicators of changes in the condition of schizophrenia.